Home › Compare › TRXPF vs ORCC

TRXPF vs ORCC: Dividend Comparison 2026

TRXPF yields 3.27% · ORCC yields 9.79%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRXPF wins by $634.91M in total portfolio value
10 years
TRXPF
TRXPF
● Live price
3.27%
Share price
$24.57
Annual div
$0.80
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$634.94M
Annual income
$599,684,359.43
Full TRXPF calculator →
ORCC
ORCC
● Live price
9.79%
Share price
$13.48
Annual div
$1.32
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.4K
Annual income
$1.04
Full ORCC calculator →

Portfolio growth — TRXPF vs ORCC

📍 TRXPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRXPFORCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRXPF + ORCC cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRXPF pays
ORCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRXPF
Annual income on $10K today (after 15% tax)
$277.78/yr
After 10yr DRIP, annual income (after tax)
$509,731,705.52/yr
ORCC
Annual income on $10K today (after 15% tax)
$832.34/yr
After 10yr DRIP, annual income (after tax)
$0.88/yr
At 15% tax rate, TRXPF beats the other by $509,731,704.63/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRXPF + ORCC for your $10,000?

TRXPF: 50%ORCC: 50%
100% ORCC50/50100% TRXPF
Portfolio after 10yr
$317.48M
Annual income
$299,842,180.23/yr
Blended yield
94.44%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ORCC right now

TRXPF
No analyst data
Altman Z
5.8
Piotroski
3/9
ORCC
Analyst Ratings
9
Buy
4
Hold
1
Sell
Consensus: Buy
Price Target
$16.00
+18.7% upside vs current
Range: $16.00 — $16.00
Altman Z
0.5
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRXPF buys
0
ORCC buys
0
No recent congressional trades found for TRXPF or ORCC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRXPFORCC
Forward yield3.27%9.79% ✓
Annual dividend / share$0.80$1.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100% ✓-50%
Portfolio after 10y$634.94M ✓$21.4K
Annual income after 10y$599,684,359.43 ✓$1.04
Total dividends collected$632.35M ✓$1.0K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: TRXPF vs ORCC ($10,000, DRIP)

YearTRXPF PortfolioTRXPF Income/yrORCC PortfolioORCC Income/yrGap
1← crossover$11,354$653.59$11,190$489.61+$164.00 → TRXPF
2$13,535$1,387.04$12,229$256.01+$1.3K → TRXPF
3$17,574$3,090.80$13,216$130.74+$4.4K → TRXPF
4$26,305$7,500.82$14,207$66.02+$12.1K → TRXPF
5$49,132$20,985.78$15,234$33.17+$33.9K → TRXPF
6$125,837$73,265.77$16,317$16.62+$109.5K → TRXPF
7$485,391$350,745.93$17,468$8.32+$467.9K → TRXPF
8$3,048,220$2,528,851.81$18,695$4.16+$3.03M → TRXPF
9$32,945,707$29,684,110.82$20,006$2.08+$32.93M → TRXPF
10$634,936,266$599,684,359.43$21,407$1.04+$634.91M → TRXPF

TRXPF vs ORCC: Complete Analysis 2026

TRXPF — Stock

Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent used for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; allergen immunotherapy tablets comprising CEDARCURE and MITICURE; and CORECTIM, a topical janus kinase (JAK) inhibitor. It markets its products primarily through medical representatives for medical professionals. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc.

Full TRXPF Calculator →

ORCC — BDC

Owl Rock Capital Corporation is a business development company. The fund makes investments in senior secured or unsecured loans, subordinated loans or mezzanine loans and also considers equity-related securities including warrants and preferred stocks also pursues preferred equity investments and common equity investments. Within private equity, it seeks to invest in growth, acquisitions, market or product expansion, refinancings and recapitalizations. It seeks to invest in middle market companies based in the United States, with EBITDA between $10 million and $250 million annually and/or annual revenue of $50 million and $2.5 billion at the time of investment.

Full ORCC Calculator →
📬

Get this TRXPF vs ORCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRXPF vs SCHDTRXPF vs JEPITRXPF vs OTRXPF vs KOTRXPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.